Vitalis Therapeutics Inc. — Pharmacovigilance and expedited safety reporting for the VitaFlow (VTX-401) program: the four-part test, the 7-day and 15-day regulatory clocks under 21 CFR 312.32, case flow, signal detection, and the compliance position at 15 October 2026.
1. Why This Sits Outside Program Governance
Almost everything in this suite describes decisions the program makes. This document describes obligations the program has, whether or not it finds them convenient.
No gate can defer a 15-day report. No contingency draw buys an extension. The Development Committee cannot vote to delay one, and a Program Director who allowed schedule pressure to slow a submission would have committed a regulatory violation, not a governance error.
For a program manager arriving from an industry with a single chain of command, this is the mental adjustment that matters most: some clocks are not yours. The job is to build a process that meets them without heroics, and then to leave it alone.
2. The Four-Part Test
The vocabulary here is precise and the words do not mean what everyday usage suggests. An event must clear all four of these tests before an expedited report is required.
| Concept | Abbr. | Definition | What it actually means |
|---|---|---|---|
| Adverse event | AE | Any untoward medical occurrence in a participant administered a drug, whether or not considered drug related. | Broadest category. Collected on every participant at every visit. |
| Serious | SAE | Results in death, is life-threatening, requires or prolongs inpatient hospitalization, causes persistent or significant disability, is a congenital anomaly, or requires intervention to prevent one of the above. | A regulatory definition, not a clinical severity judgment. A severe headache is not serious; an overnight admission for observation is. |
| Unexpected | — | Not listed in the Investigator Brochure, or not listed at the observed specificity or severity. | Assessed against the current IB, which changes as the safety database grows. An event unexpected in 2025 may be expected in 2027. |
| Suspected adverse reaction | SAR | There is evidence suggesting a causal relationship between the drug and the event. | The narrowing test. Mere temporal association is not evidence of causality. |
Severity describes how bad the event felt. Seriousness describes whether it met one of six defined outcomes. Only the second one starts a clock.
The narrowing is substantial. Every participant generates adverse events; a minority are serious; of those a minority are unexpected against the current Investigator Brochure; and of those only the ones with evidence suggesting causality are suspected adverse reactions. In this program, 214 serious adverse events have been reported and 44 required expedited submission.
Note the moving target in the third test. Expectedness is assessed against the current Investigator Brochure, and the IB is updated as the safety database grows — this program is on version 4. An event that was unexpected in 2025 may be expected in 2027, and the reporting obligation changes with it. That makes IB currency a compliance matter rather than documentation housekeeping.
3. Expedited Reporting Obligations
| Trigger | Deadline | Clock starts at | Action | Reference |
|---|---|---|---|---|
| Unexpected fatal or life-threatening suspected adverse reaction | 7 calendar days | Sponsor's initial receipt of the information | Notification to FDA. Written report follows. | 312.32(c)(2) |
| Suspected adverse reaction that is both serious and unexpected | 15 calendar days | Sponsor's determination that it qualifies for reporting | IND Safety Report to FDA and all participating investigators, Form FDA 3500A. | 312.32(c)(1)(i) |
| Findings from other studies, animal or in vitro testing suggesting significant human risk | 15 calendar days | Determination that it qualifies | IND Safety Report. Applies to non-clinical findings too. | 312.32(c)(1)(ii)-(iii) |
| Clinically important increase in the rate of a serious suspected adverse reaction | 15 calendar days | Determination that it qualifies | Rate change against the protocol or Investigator Brochure. | 312.32(c)(1)(iv) |
| Additional information requested by FDA | 15 calendar days | Receipt of the request | As specified by the agency. | 312.32(c)(1)(v) |
| Event initially assessed as non-reportable, later determined reportable | 15 calendar days | The determination | Follow-up investigation obligation. | 312.32(d)(3) |
The 7-day clock — unexpected fatal or life-threatening — runs from the sponsor's initial receipt of the information. It starts the moment the information arrives, before anyone has assessed anything.
The 15-day clock — serious and unexpected suspected adverse reaction — runs from the sponsor's determination that the information qualifies for reporting. Assessment time sits inside the process rather than inside the clock.
The practical consequence: for a fatal or life-threatening case there is no assessment grace period at all. Seven days from the phone call, not seven days from working out what happened. That asymmetry is why the internal SAE reporting obligation at §4 is set at 24 hours — tighter than any regulation requires.
Reports go to FDA and to every participating investigator on the IND, not only to the site that reported the event. An investigator at a different site is entitled to know what has been seen elsewhere, because it changes what they tell their own participants.
4. Case Flow
| Step | Timing | Owner | Detail |
|---|---|---|---|
| Site identifies event | Immediate | Investigator | Recorded in the eCRF. Seriousness and causality assessed by the investigator. |
| SAE reported to sponsor safety | 24 hours of site awareness | Investigator / site | Contractual and protocol obligation, tighter than the regulatory clock so the sponsor has time to assess before its own deadline starts. |
| Triage and case processing | Same business day | Pharmacovigilance | Seriousness, expectedness against the current IB, and sponsor causality assessment. |
| Medical review | Within 48 hours | Medical monitor | Sponsor causality assessment. Where sponsor and investigator disagree, the more conservative assessment governs. |
| Regulatory submission | Per the clocks above | Regulatory operations | Form FDA 3500A to the CDER review division; copy to all participating investigators. |
| Investigator notification | With the submission | Pharmacovigilance | Every investigator on the IND, not only the reporting site. |
| IRB notification | Per local IRB requirement | Site | Site obligation, but tracked centrally because failure is a site-level GCP finding. |
Building the internal deadline inside the regulatory one is how a process meets its obligations without heroics. Current median site-to-sponsor time on this program is 19 hours.
Where the investigator and the sponsor's medical monitor disagree on causality, the more conservative assessment governs. If either party considers the event drug-related, it is treated as a suspected adverse reaction. A sponsor that resolved causality disputes in its own favor would be deciding its own reporting obligations.
5. Signal Detection
Individual case reporting is a legal obligation. Signal detection is the analytical work that finds a pattern no single case reveals.
| Activity | Frequency | Purpose |
|---|---|---|
| Aggregate rate review | Monthly | Blinded pooled rates by system organ class against the Investigator Brochure. |
| Targeted event monitoring | Continuous | GI events, hepatic events and MACE are followed individually against pre-specified thresholds — these are the class and program exposures (R-02). |
| DMC unblinded review | Every 16 weeks | The only unblinded look. See the DMC Charter. |
| DSUR | Annually | Development Safety Update Report — the cumulative safety picture, submitted to regulators on the IND anniversary. |
| Investigator Brochure update | As required | When an event becomes expected, the reporting obligation for future occurrences changes. IB currency is therefore a compliance matter, not documentation housekeeping. |
Only the Data Monitoring Committee can see the split. The sponsor's role is to surface the pattern; the committee's role is to look at it unblinded and decide whether it matters.
Three areas are followed individually rather than through aggregate review: gastrointestinal events, because tolerability is the program's differentiation claim and its principal clinical risk (R-02); hepatic events, because any case meeting Hy's Law criteria triggers an ad hoc DMC review within five working days; and adjudicated cardiovascular events in the CR-02 sub-study.
6. Compliance Position at 15 October 2026
| Measure | Value | Note |
|---|---|---|
| Serious adverse events reported | 214 | Cumulative across the program |
| 7-day expedited reports | 3 | Unexpected fatal or life-threatening |
| 15-day expedited reports | 41 | Serious and unexpected SARs |
| Submitted within the regulatory window | 100% | The only acceptable value. A single late report is a finding at inspection. |
| Median site-to-sponsor notification | 19 hours | Against a 24-hour internal obligation |
| Investigator Brochure version | v4 | Expectedness assessed against this |
| DSURs submitted | 2 | Annual, on the IND anniversary |
There is no acceptable rate of late safety reporting, because the failure mode is not a variance against plan — it is a regulator, or a participant's family, discovering that the sponsor knew something and did not say so on time. Programs recover from budget overruns and schedule slips. This is the category where a single instance can end a filing.
7. Responsibilities
| Activity | Meridian (CRO) | Vitalis (sponsor) |
|---|---|---|
| SAE collection from sites | Executes | Sets the 24-hour obligation |
| Case processing and coding | Executes | Approves conventions |
| Seriousness assessment | Applies the definition | Adjudicates disputes |
| Expectedness assessment | — | Retained — requires IB judgment |
| Sponsor causality assessment | — | Retained — medical monitor |
| Regulatory submission | Prepares | Retained — sponsor is the IND holder |
| Investigator notification | Distributes | Approves content |
| Signal detection | Supplies aggregate data | Retained |
| DSUR authorship | Contributes | Retained |
| IB maintenance | — | Retained |
The retained column is longer here than anywhere else in the program, including the Site Management Plan. That is not a preference. The sponsor holds the IND, and every reporting obligation in §3 attaches to the IND holder. Execution can be contracted; the obligation cannot.